Chromocell Therapeutics Corporation (CHRO)
+0.070 (4.00%)
May 20, 2024, 3:59 PM EDT - Market closed

Company Description

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain.

The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family.

Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.

Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Chromocell Therapeutics Corporation
Chromocell Therapeutics logo
Country United States
Founded 2002
IPO Date Feb 16, 2024
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Francis Knuettel II, M.B.A.

Contact Details

685 Us Highway One
North Brunswick, New Jersey 08902
United States
Phone (917) 644-6313

Stock Details

Ticker Symbol CHRO
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.00
CIK Code 0001919246
Employer ID 86-3335449
SIC Code 2836

Key Executives

Name Position
Francis Knuettel II, M.B.A. Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary
Dr. Eric Lang M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 15, 2024 424B3 Prospectus
May 15, 2024 424B3 Prospectus
May 15, 2024 10-Q Quarterly Report
Apr 17, 2024 POS EX Filing
Apr 17, 2024 424B3 Prospectus
Apr 17, 2024 424B3 Prospectus
Apr 16, 2024 10-K Annual Report
Apr 15, 2024 S-8 Securities to be offered to employees in employee benefit plans
Apr 9, 2024 8-K Current Report
Apr 1, 2024 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405